Table 4.
Phase 2 EGFR-T790M Positivity Rate Per Center
| Local Laboratory # | # Cases | # Positive Cases (Local Laboratory) | # Positives Cases (Reference Laboratory) | a% Positive Cases |
|---|---|---|---|---|
| Laboratory 1 (ddPCR) | 52 | 13 | 13 | 25.0 |
| Laboratory 2 (NGS – Oncomine Lung cfDNA) | 10 | 2 | 2 | 20.0 |
| Laboratory 3 (NGS – Illumina TST15) | 35 | 8 | 8 | 22.9 |
| Laboratory 4 (Cobas) | 8 | 3 | 3 | 37.5 |
| Laboratory 5 (Entrogen) | 12 | 5 | 4 | 33.3 |
| Laboratory 6 (Entrogen) | 7 | 0 | 1 | 14.3 |
| Laboratory 7 (Cobas) | 16 | 0 | 1 | 6.3 |
| Total | 140 | 31 | 32 | 22.9 |
#, number; cfDNA, cell-free DNA; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; TST15, TruSight Tumor 15.
a
Percent positive cases were based on cases detected by reference laboratory.